

**REMARKS:**

Claims 2, 15-17 and 22 are in the case and presented for reconsideration. Claim 22 is a new claim.

Claims 2 and 15-17 were rejected under 35 U.S.C. § 102(b) as being anticipated by Dietmann et al. (U.S. Patent 3,506,653).

Claim 2 has been amended to eliminate the compounds disclosed in Dietmann et al., so that claim 2, and its dependent claims 15-17, are now believed to be allowable.

Dietmann et al. teaches the activity of certain adenosine derivatives (see compounds E, G, H, I, K, N, O) on cardiac and vascular systems. The reference also mentions the administration of the adenosine derivatives in the form of an intravenous solution. Accordingly, in order to overcome the teaching of Dietmann et al. as cited by the Examiner, compounds E, G, H, I, K, N, O were deleted from the claim 2.

New claim 22 is directed to the use of the pharmaceutical claim of 17 to treat certain conditions. Support for this amendment may be found at least at paragraph [0084] of the published application.

Accordingly the claims as presently submitted for consideration are believed to be patentable and, by this amendment, the application and claims are believed to be in condition for allowance. If any matters remain, the Examiner is invited to call the

undersigned and in any case favorable action is respectfully requested.

Respectfully submitted,

/NADER A. ABADIR/  
Nader A. Abadir  
Reg. No. 52,537  
Attorney for Applicants  
(845) 359-7700

Dated: February 11, 2009

**NOTARO & MICHALOS P.C.**  
100 Dutch Hill Road, Suite 110  
Orangeburg, New York 10962-2100

**Customer No. 21706**